|
|
|
|
|
|
Sponsored by: |
Inspire Pharmaceuticals |
Information provided by: | Inspire Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00403715 |
The purpose of this trial is to compare the effectiveness and safety of INS365 Ophthalmic Solution with Placebo when applied topically in subjects with dry eye disease.
Condition | Intervention | Phase |
Dry Eye Disease |
Drug: diquafosol tetrasodium (INS365) Ophthalmic Solution |
Phase III |
MedlinePlus related topics: | Eye Diseases |
ChemIDplus related topics: | Ins 365 Diquafosol |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Multi-Center, Double-Masked, Randomized, Placebo-Controlled, Dose-Ranging Study of Multiple Ocular Instillations of INS365 Ophthalmic Solution vs. Placebo in Subjects With Dry Eye Disease |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 03-104 |
First Received: | November 22, 2006 |
Last Updated: | November 22, 2006 |
ClinicalTrials.gov Identifier: | NCT00403715 |
Health Authority: | United States: Food and Drug Administration |
|